Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

Authors

  • Md Abdul Ahad Assistant Professor, Department of Gastroenterology, Rajshahi Medical College
  • Md Abdul Alim Assistant Professor, Department of Gastroenterology, Rajshahi Medical College
  • Abhijit Guho Medical Officer, Department of Microbiology, Rajshahi Medical College
  • Quazi Tarikul Islam Professor and Head, Department of Medicine, Rajshahi Medical College
  • Khan Abul Kalam Azad Professor, Department of Medicine. Dhaka Medical College, Dhaka

DOI:

https://doi.org/10.3329/jom.v10i2.2817

Keywords:

Hepatitis B vaccine

Abstract

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals.  

doi: 10.3329/jom.v10i2.2817

J MEDICINE 2009; 10 : 67-76

Downloads

Download data is not yet available.
Abstract
873
PDF
1302

Author Biography

Md Abdul Ahad, Assistant Professor, Department of Gastroenterology, Rajshahi Medical College

Assistant Professor, Department of Gastroenterology, Rajshahi Medical
College, Bangladesh

Downloads

How to Cite

Ahad, M. A., Alim, M. A., Guho, A., Islam, Q. T., & Azad, K. A. K. (2009). Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination. Journal of Medicine, 10(2), 67–76. https://doi.org/10.3329/jom.v10i2.2817

Issue

Section

Original Articles